Hoffman-Censits, J, Tsiatas, M, Chang, PMH, Kim, M, Zagouri, F, Shin, SJ, Kim, SH, Su, HYL, Arija, JAA, Maroto-Rey, JP, Antonuzzo, L, Maruzzo, M, Tambaro, R, Blais, N, Rottey, S, Gakis, G, Schneider, A, Tyroller, K, Jacob, N, Valderrama, BP. Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.739. PMID:. IF:41.900(Q1/1D).

Gregorc, V, Majem, M, Lo Russo, G, Maio, M, Salvagni, S, Gutiérrez-Calderon, V, Gonzalez-Cao, M, Contreras, SS, Koumarianou, A, Bearz, A, Bernabé-Caro, R, Viteri, S, de Sanmamed, MF, Zagouri, F, Bueno, TM, Lazzari, C, Martínez-Recio, S, Giménez-Capitán, A, Zhang, Y, Shan, Y, Zhu, HQ, Zhao, CQ, Shen, HG, Wang, Y, Rosell, R. Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. LANCET ONCOLOGY. 2026; 27(4)DOI:10.1016/S1470-2045(25)00764-8. PMID:41926959. IF:35.900(Q1/1D).

Garcia, AM, Rezqallah-Arón, A, Duran-Lozano, L, López-Fernández, A, Darder, E, Alfonso, R, Cartró, M, Cruellas, M, Reig-Jané, J, Roqué, A, Tuset, N, Cajal, TRY, Brunet, J, Balmaña, J. Evaluating the added value of a multifactorial model over gene-based risk estimates in breast cancer prediction for healthy carriers of pathogenic variants. EUROPEAN JOURNAL OF CANCER. 2026; 237DOI:10.1016/j.ejca.2026.116560. PMID:. IF:7.100(Q1/2D).

Villarrubia, JE, Fita, MJJ, de Liaño, AG, Cerrillomd, JM, Cruz, P, Anguera, G, Puente, J, Torras, OR, Navarro-Gorro, N, Pinto, A, Ruiz, SG, Cacho, D, Maeso, IG, González, NS, Lainez, N, Herranz, UA, Carrera-Lasfuentes, P, Climent, MA, Macías, NR, Castellano, D. Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.700. PMID:. IF:41.900(Q1/1D).

Martin-Broto, J, Strauss, SJ, Palmerini, E, Valverde, C, Sebio, A, Redondo, A, Stacchiotti, S, Grignani, G, Aliberti, S, Diaz-Beveridge, R, Billalabeitia, EG, Cruz, J, Carrasco-Garcia, I, Ibrahim, T, Diaz-Martin, J, Salguero-Aranda, C, Gutierrez, A, Mayordomo-Aranda, E, Ramos, R, Merino, J, Collini, P, Tirabosco, R, Bague, S, Romagosa, C, Carrera, MA, Ledesma, P, Hindi, N, Moura, DS. IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort. Cancer Communications. 2026; 46DOI:10.34133/cancomm.0015. PMID:41836677. IF:24.900(Q1/1D).

Holgado, A, Llansana, A, Vázquez, C, Gallego, O, Aguado, M, Valero, C, León, X. Identification of prognostic variables in patients with recurrent head and neck squamous cell carcinoma treated with salvage surgery: Implications for treatment with immunotherapy. ORAL ONCOLOGY. 2026; 175DOI:10.1016/j.oraloncology.2026.107903. PMID:41722172. IF:3.900(Q1/2D).

Mezquita, L, Vicente-Herrero, MT, Cruz, P, de la Torre, MVRI, Hidalgo-Coloma, J, Garcia, LC, Gallego, O, Calvo, A, Martinez, K, Perez-Altozano, J, Molina, R, Garcia-Pardo, M, Gutierrez-Sainz, L, Moreno-Atahonero, E, Ore-Arce, M, Serrano, C, Terradillos-Garcia, MJ, Valero, MR, Reinoso-Barbero, L, Rodriguez, CA, Calvo-Cerrada, B. SEOM-AEEMT consensus on occupational cancer and cancer-associated disability. Clinical & Translational Oncology. 2026; 28(3)DOI:10.1007/s12094-025-04037-2. PMID:40956506. IF:2.500(Q3/6D).

Samsó, RH, Cabré, LC, Abós, SG, Solerdelcoll, MS, Majercakova, K, García, AS, Alegria, IG, Garrido, MF, Duarte, AM, López, JAG. Multidisciplinary Treatment of Inguinoscrotal Sarcomas: Analysis of 39 Cases Treated by Surgical Approach. Cancers. 2026; 18(5)DOI:10.3390/cancers18050876. PMID:41827809. IF:4.400(Q2/3D).